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syndrome
Antiplatelet agents reduce mortality from acute coronary
syndrome (ACS). Aspirin, clopidogrel, glycoprotein IIb/IIIa
inhibitors and newer agents such as prasugrel or ticagrelor are
now used routinely in ACS and with percutaneous coronary
intervention (PCI). Although currently available antiplatelet
therapies are highly effective, they cannot nullify athero-
thrombotic risk. Recurrent ischaemic events occur despite
treatment with aspirin and/or clopidogrel, the most widely
prescribed antiplatelet drugs.1 Breakthrough ischaemic
events may reflect the inability of these agents to fully
suppress the stimulus for platelet activation at sites of plaque
disruption, or they may be the result of resistance to the
antiplatelet effects of aspirin or clopidogrel.2 Aggressive risk
factor profiles, genetic background and a heightened throm-
botic state can all play a part in the recurrence of ischaemic
events.
One of the most feared complications in patients with ACS
undergoing PCI is stent thrombosis (ST), which has an unac-
ceptably high mortality rate of about 45%.3 The rate of stent
thrombosis remains high even in the newer studies where
state-of-the-art antiplatelet therapy was deployed. For
instance, in the Therapeutic Outcomes by Optimizing Platelet
Inhibition with PrasugreleThrombolysis in Myocardial
Infarction (TRITONeTIMI) 38 trial of prasugrel, the rates of
stent thrombosis in the patients treated with prasugrel and
clopidogrel were 1.1% and 2.4%, respectively at 450 days
follow-up.4 The Acute Catheterization and Urgent Interven-
tion Triage strategy (ACUITY) and Harmonizing Outcomes
with Revascularization and Stents in Acute Myocardial
Infarction (HORIZONS-AMI) trials confirmed that the* Corresponding author. Tel.: þ44 7812 132331 (mobile).
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major research efforts to find the consummate antiplatelet
agent; one that would have a rapid onset of action, deliver
complete platelet blockade, be fully reversible and provide
optimal anti-ischaemic effects in the absence of an increase in
bleeding risk.2. What are PAR-1 inhibitors?
Protease-activated receptor-1 (PAR-1) inhibitors are a new
class of antiplatelet agents which affect platelets via path-
ways that are different from that of currently used agents.
Whilst aspirin acts on platelets via the thromboxane pathway
and clopidogrel, prasugrel and ticagrelor act via inhibition of
the platelet adenosine diphosphate (ADP) receptor P2Y12, PAR-
1 inhibitors target thrombin-induced platelet aggregation.
Thrombin, a serine protease is the most potent physiological
agonist of platelets and responsible for the generation of
fibrin. Thrombin receptor signalling in platelets ismediated by
protease-activated receptors (PARs) PAR-1 and PAR-4, which
are essentially G-protein-linked members of the 7-
transmembrane domain receptor superfamily.7 PAR-1 is
activated by subnanomolar concentrations of thrombin and is
likely the primary platelet thrombin receptor in humans.8
Vorapaxar and atopaxar are the two main PAR-1 inhibitors
that have been evaluated in clinical studies. Vorapaxar has
been shown to selectively and potently inhibit thrombin-
induced platelet aggregation in experimental studies.9,10
Atopaxar has been shown to have synergistic effects with
aspirin and a combination of aspirin and clopidogrel in
human volunteers.11ty of India. All rights reserved.
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Vorapaxar (SCH 530348; Merck, Whitehouse Station, NJ, USA)
is rapidly absorbed following oral administration, has high
bio-availability and results in potent, selective and reversible
PAR-1 inhibition.12 The phase 2 programme of vorapaxar
consisted of three randomized trials. The first, in patientswith
stable coronary artery disease (CAD) undergoing elective PCI,
the TRA-PCI13 and two studies in Japanese patients with ACS
or a history of stroke.14,15 In TRA-PCI, of the 1030 patients
undergoing PCI, nearly all were on aspirin and clopidogrel and
randomized to receive one of three doses of vorapaxar or
placebo. The primary endpoint of Thrombolysis In Myocardial
Infarction (TIMI) major and minor bleeding was similar
between the vorapaxar and placebo arms. The platelet sub-
study of TRA-PCI showed dose-dependent platelet inhibi-
tion.13 The composite ischaemic endpoint was numerically
lower in the pooled vorapaxar groups, mainly due to a reduc-
tion in PCI-related myocardial infarction (MI). The Japanese
ACS study demonstrated the outcomes that were similar to
the TRA-PCI trial.14 The Japanese stroke studywas a small one
with 90 patients in which few overall events were docu-
mented.15 These studies served as impetus for two phase 3
studies of vorapaxar that are discussed below.3.1. Vorapaxar in acute coronary syndrome
Vorapaxar was tested in the phase 3 Thrombin Receptor
Antagonist for Clinical Event Reduction in Acute Coronary
Syndrome (TRACER) trial in which it was compared against
placebo in nearly 13,000 patients presenting with Non-ST-
segment Elevation Acute Coronary Syndrome (NSTE-ACS).16
Most of the patients in the study were already on dual anti-
platelet therapy at entry. The studywas terminated early after
a safety review, owing to a significantly increased incidence of
bleeding including intracranial haemorrhage in the vorapaxar
arm. After a median follow-up of 502 days, there was no
difference in the incidence of the composite primary endpoint
of death from cardiovascular causes, MI, stroke, recurrent
ischaemia with rehospitalisation, and/or urgent coronary
revascularization, between the two arms (2-year cumulative
event rate, 18.5% vs. 19.9%; hazard ratio [HR], 0.92; 95%
confidence interval [CI], 0.85e1.01; P ¼ 0.07). Death from
cardiovascular causes occurred less frequently in the vor-
apaxar compared to placebo group (14.7% and 16.4%, respec-
tively; HR, 0.89; 95% CI, 0.81e0.98; P ¼ 0.02). Rates of moderate
and severe bleeding were significantly higher with vorapaxar
compared to placebo (7.2% vs. 5.2%; HR, 1.35; 95% CI,
1.16e1.58; P < 0.001). In addition, incidence of intracranial
bleeding was higher with vorapaxar (1.1% vs. 0.2%; HR 3.39;
95% CI, 1.78e6.45; P < 0.001).16
To put this in perspective, there was an absolute excess at
two years of two moderate or severe bleeds, approximately
one additional intracranial haemorrhage, and about five
Thrombolysis InMyocardial Infarction criteria (TIMI) clinically
relevant bleeds for every 100 patients treated. The trial was
therefore terminated early due to this unacceptable high
bleeding incidence. And the bleeding risk came with the
additional drawback of a failure to achieve a reduction in theprimary endpoint. The increased bleeding was thought to be
secondary to an interaction between vorapaxar and thieno-
pyridine, but the evidence for this was not striking.
3.2. Vorapaxar in secondary prevention
The other large phase 3 vorapaxar trial was the Thrombin
Receptor Antagonist in Secondary Prevention of Athero-
thrombotic Ischemic Events (TRA 2P)-Thrombolysis In
Myocardial Infarction (TIMI) 50 trial, that was published
slightly ahead of the TRACER trial.17 Over 26,000 patients with
a history of recent MI (67% of study population), ischaemic
stroke or transient ischaemic attack (19%), or peripheral
arterial disease (14%) within the preceding 2 weeks to 12
months, were randomized to receive vorapaxar or placebo.17
After 2 years, the data and safety monitoring board recom-
mended discontinuation of the study treatment in patients
with a history of stroke due to an unacceptably high risk of
intracranial haemorrhage. The studywas however, allowed to
be continued in the rest of the patients.
At 3 years follow-up, the primary endpoint had occurred in
1028 patients (9.3%) in the vorapaxar group and 1176 patients
(10.5%) in the placebo group (HR, 0.87; 95% CI, 0.80e0.94;
P < 0.001). The pre-specified secondary endpoints of cardio-
vascular death, MI, stroke, or recurrent ischaemia leading to
revascularization also occurred less frequently with vor-
apaxar arm compared to placebo e 1259 patients (11.2%)
versus 1417 patients (12.4%) (HR, 0.88; 95% CI, 0.82e0.95;
P ¼ 0.001). The ischaemic reduction was most pronounced in
the patients with prior MI.17
But these endpoint reductions came at the cost of
increased bleeding; nearly all measures of major bleeding
were increased in the vorapaxar arm of the trial. Moderate or
severe bleeding as per the Global Utilization of Streptokinase
and Tissue Plasminogen Activator for Occluded Coronary
Arteries (GUSTO) criteria was higher with vorapaxar (4.2% vs.
2.5%, HR 1.66; 95% CI 1.43e1.93; P < 0.001). TIMI clinically
significant bleeding (15.8% vs. 11.1%, HR 1.46; 95% CI
1.36e1.57; P< 0.001) and intracranial bleeding (1% vs. 0.5%, HR
1.94; 95% CI 1.39e2.70; P< 0.001) were also significantly higher
with vorapaxar compared with placebo.17
Use of dual antiplatelet therapy beyond one year following
ACS events can be fraught with complications. The patients in
the TRA 2P-TIMI 50 had suffered recent atherothrombotic
events. Accordingly, the vast majority of them were already
on dual antiplatelet therapy; many on thienopyridines and
other agents such as dipyridamole were also used at the
individual clinicians’ discretion. Hence adding vorapaxar on
top of conventional antiplatelet treatment and continuing the
same beyond one year could have heightened the bleeding
risk. Indeed, the large Clopidogrel for High Atherothrombotic
Risk and Ischemic Stabilization, Management, and Avoidance
(CHARISMA) trial that was conducted in the previous decade,
failed to find benefit for dual aspirin and clopidogrel therapy
for secondary prevention beyond one year.1
The trialists argued that for the group with no prior history
of stroke and body weight over 60 kg, vorapaxar offered net
benefit. For this group, the number needed to treat to prevent
one event was 53 and the number needed to cause a severe
bleed or intracranial haemorrhagewere comparatively high at
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were 148 fewer adverse cardiovascular events and 171 greater
moderate or severe bleeds, including 49 instances of intra-
cranial bleeding in the trial, scored against vorapaxar.
The US Food and Drugs Administration (FDA) is yet to pass
its judgement on Vorapaxar. The UK National Institute of
Health and Clinical Excellence (NICE) has not reviewed this
drug as yet.4. Atopaxar
Atopaxar (E5555, Eisai, Co. Ltd, Tokyo, Japan) is a potent and
reversible PAR-1 inhibitor. Its actions are more rapidly
reversible compared to vorapaxar. Atopaxar was tested in
a large phase 2 programme called LANCELOT which
comprised four cohesive trials with a common endpoint-
definition. The first two were conducted in Japanese patients
with ACS (n ¼ 241) and CAD (n ¼ 263) respectively.18 Patients
were already on aspirin and randomized to receive varying
doses of atopaxar following loading versus placebo. Bleeding
according to the Clopidogrel in Unstable Angina to Prevent
Recurrent Events (CURE) scale was similar between the pooled
vorapaxar and placebo groups. Non-major TIMI bleeding was
numerically higher with the highest used dose of atopaxar.
The other two trials LANCELOT-ACS (n ¼ 603) and LANCELOT-
CAD (n ¼ 720) were similarly designed but had larger study
populations.19,20 In the LANCELOT-ACS trial, CURE major
bleeding was numerically higher in the atopaxar group versus
placebo, whereas incidence of ischaemic endpoints was
similar between the two arms.19 In the LANCELOT-CAD study
in which patients were treated for 24 weeks and had a further
4-week follow-up, outcomes were slightly different.20 Rates of
bleeding were significantly higher with atopaxar-treated
patients as measured by CURE (3.9% vs. 0.6%; P ¼ 0.03) and
TIMI criteria. This bleeding risk was observed to be dose-
dependent. Ischaemia-related events were only numerically
lower in those treated with atopaxar. Interestingly, in all four
LANCELOT studies atopaxar showed a dose-dependent
increase in liver function abnormality and prolongation of
QTc interval, but without reported symptoms. Taken as
a whole, higher doses of atopaxar although resulted in
improved platelet inhibition, increased bleeding risk. The
reduction in ischaemic endpoints during the short follow-up
periods in the studies was not convincing. The outcomes
from these phase 2 studies were therefore not resoundingly
positive, but large phase 3 trials will clearly be required to
determine the true clinical impact of atopaxar.5. Conclusion
As currently established antiplatelet therapy cannot nullify
the risk of recurrent ACS, the search has been ongoing for the
consummate antiplatelet agent, one that would effectively
negate risk without increasing bleeding incidence. PAR-1
inhibitors are a novel class of antiplatelet agents that have
been developed over the last two decades. Of the two clinically
tested PAR-1 inhibitors, vorapaxar has undergone testing in
phase 3 trials whereas atopaxar remains at the phase 2 stage.Although vorapaxar showed some promise in phase 2 studies,
the two large phase 3 trials delivered disappointing results,
primarily due to an increased risk of bleeding. Indeed, this led
to the premature termination of one of the two phase 3 trialse
the trial in patients with ACS. Surprisingly, there was
a reduction in ischaemic endpoints when vorapaxar was used
for secondary prevention but not when used in the acute
stages of ACS. The clear and present bleeding risk and lack of
endpoint reduction in ACS, does not bode well for vorapaxar.
This future of this innovative class of antiplatelet drugs,
which was once held to be bright, now seems to have turned
a deep shade of grey.Funding
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